13 Impairment of non-financial assets
A review of the recoverable amounts of the Group’s assets resulted in the recognition of impairment charges amounting to € 0 million (2017: € 1 million).
In 2017, impairment charges of € 6 million related to narcotic cough suppressants were recognized in the year. In addition, an impairment of € 1 million was concluded in respect of Metadate®. Furthermore, the impairment on inotuzumab ozogamicin, out-licensed to Pfizer, for an amount of € 6 million that had been accounted for in 2013, was reversed as Pfizer announced that the European Commission has approved Besponsa® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory Acute Lymphoblastic Leukemia (ALL)
No impairment charges for Group property, plant and equipment were recognized in 2018 (2017: € 0 million).
No reasonably possible change in a key assumption on which management has based its determination of the assets recoverable amounts would cause the assets carrying amount to exceed its recoverable amount.